Breaking Finance News

Zacks Investment Research downgraded Synergy Pharmaceuticals Inc (NASDAQ:SGYP) to Sell in a report released today.

Zacks Investment Research has downgraded Synergy Pharmaceuticals Inc (NASDAQ:SGYP) to Sell in a report released on 10/12/2016.

Previously on 8/25/2016, BTIG Research reported on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) increased the target price from $0.00 to $11.00. At the time, this indicated a possible upside of 1.52%.

Yesterday Synergy Pharmaceuticals Inc (NASDAQ:SGYP) traded 0.00% even at $5.26. The company’s 50-day moving average is $5.27 and its 200-day moving average is $4.10. With the last close up 25.76% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Volume of trade was down over the average, with 1,916,535 shares of SGYP changing hands under the typical 2,958,680

Performance Chart

Synergy Pharmaceuticals Inc (NASDAQ:SGYP)

With a total market value of $0, Synergy Pharmaceuticals Inc has 52 week low of $2.50 and a 52 week high of $7.15 .

In addition to Zacks Investment Research reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is $11.30 with 2 firms rating the stock a strong buy, 2 firms rating the stock a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Synergy Pharmaceuticals Inc (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company's uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *